Biotech Values

[I Know BS]

The conference call was great and there was a nonstop barrage of questions from big time analysts all giving ASTX the attention it deserves. I doubt the will market SG-110 themselves in the U.S though considering they don't have a sales force or manufacturing facilities. I think it may be a ploy to get a bigger upfront payment from Eisai or other partner. The earnings and cash burn were the two biggest worries and now that guidance has been revised upwards and cash burn was lower than expected we should see a very nice speculation run into the end of year data. Also AT-13387 W/Gleevec phase 2 data is due this month as per clinicaltrials.gov
http://clinicaltrials.gov/show/NCT01294202

I am a buyer for sure.